Clene Inc.
CLNN6.680USD
+0.640+10.60%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
68.27MMarket Cap
LossP/E TTM
More Details of Clene Inc. Company
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Clene Inc. Info
Ticker SymbolCLNN
Company nameClene Inc
IPO dateAug 27, 2018
CEOEtherington (Robert)
Number of employees75
Security typeOrdinary Share
Fiscal year-endAug 27
Address6550 South Millrock Drive, Suite G50
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84121
Phone18016769695
Websitehttps://clene.com/
Ticker SymbolCLNN
IPO dateAug 27, 2018
CEOEtherington (Robert)
Company Executives of Clene Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Prof. Matthew Kiernan, Ph.D.
Prof. Matthew Kiernan, Ph.D.
Independent Director
Independent Director
427.00
--
Mr. Jonathon T. Gay
Mr. Jonathon T. Gay
Independent Director
Independent Director
--
--
Mr. Robert Etherington
Mr. Robert Etherington
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David J. Matlin
Mr. David J. Matlin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Alison H. Mosca
Ms. Alison H. Mosca
Independent Director
Independent Director
--
--
Mr. Reed Neil Wilcox
Mr. Reed Neil Wilcox
Independent Director
Independent Director
--
--
Dr. Vallerie V. Mclaughlin, M.D.
Dr. Vallerie V. Mclaughlin, M.D.
Independent Director
Independent Director
--
--
Mr. Morgan R. Brown
Mr. Morgan R. Brown
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Mortenson
Mr. Mark Mortenson
Co-Founder, Chief Science Officer
Co-Founder, Chief Science Officer
28.95K
--
Mr. Shalom Jacobovitz
Mr. Shalom Jacobovitz
Independent Director
Independent Director
3.75K
--
Prof. Matthew Kiernan, Ph.D.
Prof. Matthew Kiernan, Ph.D.
Independent Director
Independent Director
427.00
--
Mr. Jonathon T. Gay
Mr. Jonathon T. Gay
Independent Director
Independent Director
--
--
Mr. Robert Etherington
Mr. Robert Etherington
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David J. Matlin
Mr. David J. Matlin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Mosca (Alison)
12.71%
General Resonance, L.L.C.
6.82%
SymBiosis Capital Management, LLC
6.30%
Matlin (David J.)
4.37%
Scoggin Management LP
2.42%
Other
67.38%
Shareholders
Shareholders
Proportion
Mosca (Alison)
12.71%
General Resonance, L.L.C.
6.82%
SymBiosis Capital Management, LLC
6.30%
Matlin (David J.)
4.37%
Scoggin Management LP
2.42%
Other
67.38%
Shareholder Types
Shareholders
Proportion
Individual Investor
19.84%
Corporation
10.21%
Venture Capital
6.30%
Investment Advisor
3.37%
Hedge Fund
2.71%
Investment Advisor/Hedge Fund
1.24%
Research Firm
0.27%
Other
56.07%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
76
1.44M
21.16%
--
2025Q3
84
1.44M
25.92%
+201.66K
2025Q2
84
1.23M
29.86%
+127.61K
2025Q1
85
1.11M
32.30%
-1.69M
2024Q4
87
1.14M
32.73%
-524.09K
2024Q3
92
1.67M
28.83%
+679.01K
2024Q2
103
993.22K
510.03%
-26.79K
2024Q1
138
1.02M
27.00%
-713.63K
2023Q4
137
1.24M
28.87%
-579.74K
2023Q3
135
1.82M
30.37%
-5.13K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Mosca (Alison)
1.31M
13.04%
+917.43K
+231.66%
Dec 31, 2024
General Resonance, L.L.C.
704.59K
7%
-3.40K
-0.48%
Aug 21, 2025
SymBiosis Capital Management, LLC
650.95K
6.46%
--
--
Sep 30, 2024
Matlin (David J.)
451.99K
4.49%
-1.00
-0.00%
Mar 25, 2025
Scoggin Management LP
142.75K
1.42%
+42.75K
+42.75%
Jun 30, 2025
The Vanguard Group, Inc.
188.36K
1.87%
+55.02K
+41.27%
Jun 30, 2025
4life Research, L.L.C.
199.84K
1.98%
-1.00
-0.00%
Dec 20, 2024
Kensington Investments, L.P.
150.33K
1.49%
--
--
Dec 31, 2024
Gay (Jonathon)
116.46K
1.16%
-1.00
-0.00%
Mar 25, 2025
Geode Capital Management, L.L.C.
68.33K
0.68%
-642.00
-0.93%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 09, 2024
Merger
20→1
Jul 09, 2024
Merger
20→1
Jul 09, 2024
Merger
20→1
Jul 09, 2024
Merger
20→1
Date
Type
Ratio
Jul 09, 2024
Merger
20→1
Jul 09, 2024
Merger
20→1
Jul 09, 2024
Merger
20→1
Jul 09, 2024
Merger
20→1
FAQs
Who are the top five shareholders of Clene Inc.?
The top five shareholders of Clene Inc. are:
Mosca (Alison) holds 1.31M shares, accounting for 13.04% of the total shares.
General Resonance, L.L.C. holds 704.59K shares, accounting for 7.00% of the total shares.
SymBiosis Capital Management, LLC holds 650.95K shares, accounting for 6.46% of the total shares.
Matlin (David J.) holds 451.99K shares, accounting for 4.49% of the total shares.
Scoggin Management LP holds 142.75K shares, accounting for 1.42% of the total shares.
Mosca (Alison) holds 1.31M shares, accounting for 13.04% of the total shares.
General Resonance, L.L.C. holds 704.59K shares, accounting for 7.00% of the total shares.
SymBiosis Capital Management, LLC holds 650.95K shares, accounting for 6.46% of the total shares.
Matlin (David J.) holds 451.99K shares, accounting for 4.49% of the total shares.
Scoggin Management LP holds 142.75K shares, accounting for 1.42% of the total shares.
What are the top three shareholder types of Clene Inc.?
The top three shareholder types of Clene Inc. are:
Mosca (Alison)
General Resonance, L.L.C.
SymBiosis Capital Management, LLC
Mosca (Alison)
General Resonance, L.L.C.
SymBiosis Capital Management, LLC
How many institutions hold shares of Clene Inc. (CLNN)?
As of 2025Q4, 76 institutions hold shares of Clene Inc., with a combined market value of approximately 1.44M, accounting for 21.16% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.75%.
What is the biggest source of revenue for Clene Inc.?
In --, the -- business generated the highest revenue for Clene Inc., amounting to -- and accounting for --% of total revenue.
